M G Jeschke1, R E Barrow, D N Herndon. 1. Shriners Hospital for Children and Department of Surgery, University of Texas Medical Branch, Galveston, USA.
Abstract
OBJECTIVE:Recombinant human growth hormone (rHGH) has been shown to increase mortality in adult trauma patients; however, little has been reported on its side effects in children. The acute phase response has been suggested to be a contributing factor to trauma mortality. Therefore, the purpose of this study was to examine the effects of exogenous rHGH on the acute phase response in pediatric bum patients. DESIGN: Prospective, randomized, double-blind study. SETTING:Shriners Hospital for Children. PATIENTS: Thermally injured pediatric patients, ranging in age from 0.1 to 16 yrs. INTERVENTIONS:Twenty-eight thermally injured children received either 0.2 mg/kg/day of rHGH or saline (placebo) within 3 days of admission and for at least 25 days. MEASUREMENTS AND MAIN RESULTS: Measurements were patient demographics, incidence of sepsis, inhalation injury, mortality, serum constitutive proteins, acute phase proteins, proinflammatory cytokines and insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3. No differences could be demonstrated in age, gender, burn size, incidence in sepsis (20% vs. 26%), inhalation injury (46% vs. 27%), or mortality (8% vs. 7%) between those receiving rHGH or placebo. Serum IGF-I and IGFBP-3 increased with rHGH treatment, whereas serum IGFBP-1 decreased compared with placebo (p < .05). Burned children treated with rHGH required significantly less albumin substitution to maintain normal levels compared with placebo (p < .05). Those receiving rHGH demonstrated a decrease in serum C-reactive protein and serum amyloid-A and an increase in serum retinol-binding protein compared with placebo (p < .05). rHGH decreased serum tumor necrosis factor-alpha and interleukin (IL)-1beta, whereas no changes were found for serum IL-1alpha, IL-6, and IL-10 compared with placebo (p < .05). Free fatty acids were elevated in burned children who received rHGH (p < .05). CONCLUSION: Data indicate that rHGH does not increase mortality. rHGH decreased acute phase proteins, tumor necrosis factor-alpha, and IL-1beta, which is associated with increases in constitutive hepatic proteins and IGF-I.
RCT Entities:
OBJECTIVE: Recombinant humangrowth hormone (rHGH) has been shown to increase mortality in adult traumapatients; however, little has been reported on its side effects in children. The acute phase response has been suggested to be a contributing factor to trauma mortality. Therefore, the purpose of this study was to examine the effects of exogenous rHGH on the acute phase response in pediatric bum patients. DESIGN: Prospective, randomized, double-blind study. SETTING: Shriners Hospital for Children. PATIENTS: Thermally injured pediatric patients, ranging in age from 0.1 to 16 yrs. INTERVENTIONS: Twenty-eight thermally injured children received either 0.2 mg/kg/day of rHGH or saline (placebo) within 3 days of admission and for at least 25 days. MEASUREMENTS AND MAIN RESULTS: Measurements were patient demographics, incidence of sepsis, inhalation injury, mortality, serum constitutive proteins, acute phase proteins, proinflammatory cytokines and insulin-like growth factor-I (IGF-I), insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3. No differences could be demonstrated in age, gender, burn size, incidence in sepsis (20% vs. 26%), inhalation injury (46% vs. 27%), or mortality (8% vs. 7%) between those receiving rHGH or placebo. Serum IGF-I and IGFBP-3 increased with rHGH treatment, whereas serum IGFBP-1 decreased compared with placebo (p < .05). Burned children treated with rHGH required significantly less albumin substitution to maintain normal levels compared with placebo (p < .05). Those receiving rHGH demonstrated a decrease in serum C-reactive protein and serum amyloid-A and an increase in serum retinol-binding protein compared with placebo (p < .05). rHGH decreased serum tumor necrosis factor-alpha and interleukin (IL)-1beta, whereas no changes were found for serum IL-1alpha, IL-6, and IL-10 compared with placebo (p < .05). Free fatty acids were elevated in burned children who received rHGH (p < .05). CONCLUSION: Data indicate that rHGH does not increase mortality. rHGH decreased acute phase proteins, tumor necrosis factor-alpha, and IL-1beta, which is associated with increases in constitutive hepatic proteins and IGF-I.
Authors: Itoro E Elijah; Ludwik K Branski; Celeste C Finnerty; David N Herndon Journal: Best Pract Res Clin Endocrinol Metab Date: 2011-10 Impact factor: 4.690
Authors: Rene Przkora; David N Herndon; Oscar E Suman; Marc G Jeschke; Walter J Meyer; David L Chinkes; Ronald P Mlcak; Ted Huang; Robert E Barrow Journal: Ann Surg Date: 2006-06 Impact factor: 12.969
Authors: Marc G Jeschke; Celeste C Finnerty; Oscar E Suman; Gabriela Kulp; Ronald P Mlcak; David N Herndon Journal: Ann Surg Date: 2007-09 Impact factor: 12.969
Authors: Ludwik K Branski; William B Norbury; David N Herndon; David L Chinkes; Amalia Cochran; Oscar Suman; Deb Benjamin; Marc G Jeschke Journal: JPEN J Parenter Enteral Nutr Date: 2009-11-02 Impact factor: 4.016
Authors: David W Hart; Steven E Wolf; David L Chinkes; Sofia O Lal; Peter I Ramzy; David N Herndon Journal: Ann Surg Date: 2002-10 Impact factor: 12.969